Synchron

We’re excited to announce the launch of our community-centered BCI registry to bring patients, carers and clinicians together to learn how #BCI is being designed to provide benefit to people with limited mobility. 🧠🧠 “We are thrilled to launch our community-centered BCI registry,” said Thomas Oxley, CEO & Founder, Synchron. “There is a grass roots movement happening with BCI. We are creating an avenue for potential users and their physicians to engage and stay connected while we prepare for the next stage of clinical trials.” Read the release: 👇👇 https://lnkd.in/enXKFMTb #neurotech #braincomputerinterface #clinicaltrials #patients

Neuralink and it’s “Elon factor” can often suck all the oxygen out of the room on #neurotech…it shouldn’t. It’s not the only player doing incredible things to help paralyzed patients communicate…there are a handful. One is NY-based Synchron that has placed an implant in 10 patients already - compared to Neuralink’s one - and helps communicate a patient’s desired actions to a tablet computer. This achieved without brain surgery, instead placing its “Stentrode” into a vein in the neck. Synchron has now integrated OpenAI GPT-4o and it’s multimodal #generativeAI capabilities to allow a patient to select from generated responses to conversations happening around them, or via text and email. We had an awesome conversation about how this intertwining of the human and AI could be transformational…take a listen. And LMK what you think. As always ✌️❤️

The company that aims to bring OpenAI directly to your brain. Synchron CEO Thomas Oxley explains how they're integrating the ChatGPT AI with their neural tech https://trib.al/reJFgu6

Our users can now communicate with the Synchron #BCI + #ChatGPT. Read the full story on how we're using generative #AI to empower autonomy and choice for our users with loss of mobility and paralysis on Bloomberg: https://lnkd.in/d6mir3_U #braincomputerinterface #neurotechnology

This is Mark. Mark has ALS and can't use his hands. He's using our #BCI, powered by OpenAI, to communicate. Watch the demo now ➡️ https://lnkd.in/e-PbCEuD

“I think BCI is going to be massive. It could be one of the largest areas in all of Medtech.��� - Tom Oxley, CEO of Synchron During our LSI USA ‘24 Fireside Chat, Kimberly Ha was joined by Thomas Oxley and Andy Rasdal who shared insights on Synchron’s approach, the challenges they've faced, and highlighted the real-world impact of BCIs. Synchron is a neurotechnology company developing an endovascular BCI designed to restore functionality in patients with severe paralysis. Currently in human clinical trials, their first product is a BCI that enables people with impaired upper limb function to control digital devices directly from the brain. Tune into the full Fireside Chat to hear more about the true potential of BCI and the approach Synchron is taking to restore independence and functionality to individuals with severe paralysis. “Neurotechnology to Address the Limitations of the Human Body” is available on our website and YouTube channel: https://lnkd.in/gin8USRx

We're heading to #ALSNexus, hosted by The ALS Association! Planning to attend? Stop by our booth or join our session on how people living with #ALS may benefit from a #BCI. 🗓️ Session Details: Tuesday, July 16th, 2:00 - 3:00pm CDT | The Future of Assistive Technology 🔗 Full Agenda: https://lnkd.in/eCD_X6Xb

Brain-computer interfaces show potential to restore function to people impacted by incurable neurological conditions such as stroke, spinal cord injury, traumatic brain injury and neurodegenerative disease. 🧠🧠🧠 Our CEO Thomas Oxley was on a panel hosted by Mount Sinai Health System at the recent Aspen Ideas Festival with experts from #neurosurgery, #neuroscience and technology to explore the current state of BCIs, their applications and the possibilities of this transformative technology. Watch the replay here: 👇👇👇 https://lnkd.in/gySxc2Et

“I think BCI is going to be massive. It could be one of the largest areas in all of Medtech.” - Thomas Oxley, CEO of Synchron In this LSI USA ‘24 Fireside Chat, Kimberly Ha is joined by Thomas Oxley and Andy Rasdal where they share insights on Synchron’s approach, and the challenges they've faced, and highlight the real-world impact of BCIs. Synchron is a neurotechnology company developing an endovascular BCI designed to restore functionality in patients with severe paralysis. Currently in human clinical trials, their first product is a BCI that enables people with impaired upper limb function to control digital devices directly from the brain. Tune into the full Fireside Chat to hear more about the true potential of BCI and the approach Synchron is taking to restore independence and functionality to individuals with severe paralysis. “Neurotechnology to Address the Limitations of the Human Body” is available on our website and YouTube channel.

Today at Aspen Ideas, Synchron CEO Thomas Oxley will speak alongside fellow Mount Sinai Health System experts from neurosurgery, neuroscience and technology on the current and future state of #BCI. Session details here: https://lnkd.in/gySxc2Et